文献速递MDS 与骨髓增殖性肿瘤白血病

阿扎胞苷下调CD4+FOXP3- T细胞IL-6/STAT3轴可能为其抗肿瘤免疫机制

Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3- T cells represents a potential antitumor mechanism of azacitidine.
PubMed 文献 · Blood Adv · 2021-01-01

该研究在73例接受阿扎胞苷治疗的高危骨髓增生异常综合征患者中,采用功能蛋白质组学、转录组学和突变分析,发现应答者CD4+ T细胞免疫反应协调且炎症细胞因子信号通路下调,非应答者则上调。阿扎胞苷介导的CD4+FOXP3-常规T细胞中IL-6诱导的STAT3磷酸化下调与更好应答和生存独立相关,且与突变数目和谱无关。

要点

  • 阿扎胞苷应答者CD4+ T细胞炎症细胞因子信号通路下调,非应答者上调。
  • Tcons中IL-6/STAT3轴下调与更好应答和生存独立相关。
  • 该下调与患者突变数目和突变谱无关。

核心结论

  • Tcons中IL-6/STAT3通路下调可能构成阿扎胞苷此前未识别的免疫介导作用机制。

研究设计与样本

  • 研究纳入73例接受阿扎胞苷治疗的高危骨髓增生异常综合征患者,采用功能蛋白质组学、转录组学和突变分析。

主要发现

  • 应答者阿扎胞苷治疗后CD4+ T细胞呈现协调的免疫反应并下调炎症细胞因子信号通路,非应答者上调相同通路。
  • 阿扎胞苷介导CD4+FOXP3-常规T细胞中IL-6诱导的STAT3磷酸化下调,与更好应答和生存独立相关。
  • 该下调与患者突变数目和突变谱无关。
  • 阿扎胞苷诱导的Tcons中IL-6/STAT3轴下调恢复了CD4+ T细胞亚群的STAT信号架构,而Tcons中IL-6/STAT3活性上调者STAT信号网络仍紊乱。

临床怎么用

  • 阿扎胞苷下调Tcons中IL-6/STAT3轴与更好应答和生存相关,提示可探索阿扎胞苷联合IL-6/STAT3轴抑制剂的合理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD4+ T cells orchestrate immune responses and are actively engaged in shaping tumor immunity. Signal transducer and activator of transcription (STAT) signaling controls the epigenetic tuning of CD4+ T-cell differentiation and polarization, and perturbed STAT signaling networks in CD4+ T cells subvert antitumor immunity in malignancies. Azacitidine (AZA), the mainstay therapy for high-risk myelodysplastic syndromes (HR-MDS), affects CD4+ T-cell polarization and function, but whether this contributes to AZA efficacy is currently unknown. By using functional proteomic, transcriptomic, and mutational analyses in 73 HR-MDS patients undergoing AZA therapy, we demonstrate that responding patients exhibited a coordinated CD4+ T-cell immune response and downregulated the inflammatory cytokine signaling pathways in CD4+ T cells after AZA, in contrast to nonresponders who upregulated the same pathways. We further observed an AZA-mediated downregulation of intereukin-6 (IL-6)-induced STAT3 phosphorylation in CD4+FOXP3- conventional T cells (Tcons) that correlated independently with better response and survival, whereas it was also not associated with the mutation number and profile of the patients. The AZA-induced downregulation of IL-6/STAT3 axis in Tcons restored the STAT signaling architecture in CD4+ T-cell subsets, whereas STAT signaling networks remained disorganized in patients who upregulated IL-6/STAT3 activity in Tcons. Given the pivotal role of CD4+ T cells in adaptive immunity, our findings suggest that the downregulation of the IL-6/STAT3 pathway in Tcons potentially constitutes a previously unrecognized immune-mediated mechanism of action of AZA and sets the scene for developing rational strategies of AZA combinations with IL-6/STAT3 axis inhibitors.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lamprianidou E, Kordella C, Kazachenka A, et al. Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3- T cells represents a potential antitumor mechanism of azacitidine. Blood Adv. 2021. PMID: 33570632. doi:10.1182/bloodadvances.2020002351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。